Abstract

Although accumulating data have investigated the effect of SARS-CoV-2 mutations on antibody neutralizing activity, less is known about T cell immunity. In this work, we found that the ancestral (Wuhan strain) Spike protein can efficaciously reactivate CD4+ T cell memory in subjects with previous Alpha variant infection. This finding has practical implications, as in many countries only one vaccine dose is currently administered to individuals with previous COVID-19, independently of which SARS-CoV-2 variant was responsible of the infection. We also found that only a minority of Spike-specific CD4+ T cells targets regions mutated in Alpha, Beta and Delta variants, both after natural infection and vaccination. Finally, we found that the vast majority of Spike-specific CD4+ T cell memory response induced by natural infection or mRNA vaccination is conserved also against Omicron variant. This is of importance, as this newly emerged strain is responsible for a sudden rise in COVID-19 cases worldwide due to its increased transmissibility and ability to evade antibody neutralization. Collectively, these observations suggest that most of the memory CD4+ T cell response is conserved against SARS-CoV-2 variants of concern, providing an efficacious line of defense that can protect from the development of severe forms of COVID-19.

Highlights

  • Immunological memory is achieved by either natural infection or vaccination and can guarantee long lasting protection from moderate to severe COVID-19, in case of SARS-CoV-2 encounter

  • We investigated the capability of circulating CD4+ T cells derived from subjects who recovered from SARS-CoV-2 infection or who were vaccinated with BNT162b2, mRNA-1273 or ChAdOx1, to respond to SARS-CoV-2 variants of concern including the recently emerged Omicron

  • To evaluate the frequency of circulating CD4+ T cells specific for Spike, we stimulated in vitro peripheral blood mononuclear cells (PBMC) with peptide pools spanning the entire ancestral (Wuhan strain) Spike sequence

Read more

Summary

Introduction

Immunological memory is achieved by either natural infection or vaccination and can guarantee long lasting protection from moderate to severe COVID-19, in case of SARS-CoV-2 encounter. Accumulating evidences have shown a relatively small impact of Alpha variant on the antibody neutralization capacity, while Beta variant is associated to a significant loss of neutralizing activity These observations were obtained both on sera from recovered individuals and from vaccinated subjects [6]. BNT162b2 and mRNA1273 mRNA vaccines (from Pfizer/Biontech and Moderna, respectively) and the viral vector based ChAdOx1 (AstraZeneca) vaccine retain high efficacy against Alpha variant [11], while a significant loss has been demonstrated for ChAdOx1 against Beta variant [12] In this manuscript, we investigated the capability of circulating CD4+ T cells derived from subjects who recovered from SARS-CoV-2 infection or who were vaccinated with BNT162b2, mRNA-1273 or ChAdOx1, to respond to SARS-CoV-2 variants of concern including the recently emerged Omicron

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call